BioMed Raises $177M to Accelerate Next-Gen Biologics Development
Harbour BioMed, a global clinical stage biopharmaceutical company developing novel therapeutics in the fields of immuno-oncology, immunologic diseases, and COVID-19,
Read more
R&D
Preventative approaches and treatment options for COVID-19
Researchers across the world are racing to develop preventative approaches and treatment options for COVID-19, including monoclonal antibodies, vaccines and
Read more
Vault Pharma designing new Vault-based Coronavirus Vaccine
Vault Pharma is collaborating with UCLA and other universities to develop a coronavirus vaccine with the capacity to treat the
Read more
Watlow’s innovative cartridge heaters help warm premature infants
Watlow’s innovative application of well-established cartridge heaters has helped a leading medical devices manufacturer in Germany develop a stand-out, high-performance
Read more
New Medicine may stop COVID-19 Pandemic ‘Without Vaccination’
A Chinese laboratory has been creating a new antibody medicine considered to have the potential to cease the coronavirus pandemic,
Read more
BioMed, Utrecht University and Erasmus discover antibody blocking SARS-CoV-2 in cells
Scientists at clinical-stage biopharmaceutical company Harbour BioMed (HBM), Utrecht University and Erasmus Medical Center announced that they have discovered a
Read more
Roche’s COVID-19 antibody test gets FDA emergency authorisation
Swiss pharma giant Roche has received Emergency Use Authorisation (EUA) from the FDA for its latest COVID-19 antibody test –
Read more
Roche’s OCREVUS (ocrelizumab) can half risk of MS impairment advance
New post-hoc analysis of six years of study data for Roche’s OCREVUS (ocrelizumab) shows earlier treatment initiation nearly halves the
Read more
Nubilaria provides free EDC for pro bono COVID-19 related ARDS study
Nubilaria is providing it’s innovative ACTide EDC system free in support of a clinical study for COVID-19 related ARDS intensive
Read more
ARTES joins fight against COVID-19 with VLP vaccine platforms
ARTES Biotechnology, a Germany-based biotechnology company specialising in process development for recombinant vaccines, has commenced the development of SARS-CoV-2 vaccine
Read more